Contact us

  • View funds and model portfolios

    Learn more about our investment products

    How to invest with us

  • Latest insights""Events and webinars""Vanguard outlook 2026""
  • Discover Vanguard 365""

    Learn and earn CPD

    In-depth research for advisers

    Tools and resources for advisers

  • About Vanguard""Contact us""Fraud prevention""

    Corporate reports

    • Contact us

    FTSE Developed World ex UK Common Contractual Fund - Institutional B Accumulation - UK Life Ins. Co. (VANDXBG)

    Related Documents
    NAV Price ()
    —
    Number of stocks
    —
    —
    Risk Indicator
    —

    About this fund

    Fund objectives

    • The Fund employs a passive management – or indexing – investment approach and seeks to track the performance of the FTSE Developed ex UK Index (the “Index”).
    • The Index is comprised of large and mid-sized company stocks in global developed markets, excluding the UK.
    • The Fund attempts to: 1. Replicate the Index by investing through physical acquisition in all, or substantially all, of the component securities of the Index, holding each in approximately the same proportion as the weighting of the Index. Where not practicable to fully replicate, the Fund will use the sampling process. 2. Remain fully invested except in extraordinary market, political or similar conditions.

    Fund facts

    Share class inception
    07 Mar 2016
    Minimum initial investment
    £30,000,000.00
    Investment structure
    Irish UCITS
    Share Class Assets'
    Total Assets
    Strategy
    Index
    Asset Class
    Equity
    Domicile
    Ireland
    Dividend schedule
    —
    Tax status
    —
    Currency
    GBP
    Legal entity
    Vanguard Investments Common Contractual Fund
    Investment manager

    Vanguard Asset Management, Ltd.
    Europe Equity Index Team

    Benchmark
    FTSE Developed ex UK Index

    The value of investments, and the income from them, may fall or rise and investors may get back less than they invested.

    Performance

    Risk and Volatility

    As at 30 Nov 2025

    Beta
    R²
    Annualized Tracking Error
    1 year
    3 years
    5 years

    Please note Beta and R-squared data will only display for funds with 3 full years of history.

    The value of investments, and the income from them, may fall or rise and investors may get back less than they invested.

    Portfolio data

    Characteristics
    FundamentalsFundBenchmarkAs at
    Number of stocks 1,885 1,890 30 Nov 2025
    Median market capital 140.4 B 140.4 B 30 Nov 2025
    24.1 x 24.1 x 30 Nov 2025
    3.6 x 3.6 x 30 Nov 2025
    19.6% 19.6% 30 Nov 2025
    21.8% 21.8% 30 Nov 2025
    Portfolio turnover rate -7.7% — 30 Sep 2025

    Market allocation

    As at 30 Nov 2025

    CountryRegionFundBenchmarkVariance +/-
    United States of AmericaNorth America 72.67% 72.74% -0.07%
    JapanPacific 6.62% 6.60% 0.02%
    CanadaNorth America 3.39% 3.40% -0.01%
    FranceEurope 2.41% 2.63% -0.22%
    SwitzerlandEurope 2.38% 2.38% 0.00%
    GermanyEurope 2.33% 2.31% 0.02%
    AustraliaPacific 1.81% 1.80% 0.01%
    South KoreaPacific 1.56% 1.56% 0.00%
    NetherlandsEurope 1.16% 1.16% 0.00%
    SpainEurope 0.93% 0.93% 0.00%
    ItalyEurope 0.86% 0.87% -0.01%
    SwedenEurope 0.83% 0.83% 0.00%
    Hong KongPacific 0.58% 0.58% 0.00%
    DenmarkEurope 0.45% 0.45% 0.00%
    SingaporePacific 0.38% 0.38% 0.00%

    Holdings details

    As at 30 Nov 2025

    Holding name% of market valueSectorRegionMarket valueShares
    NVIDIA Corp 5.18305% Technology US £67,010,488.27 495,106
    Apple Inc 5.00539% Technology US £64,713,623.51 308,419
    Microsoft Corp 4.47282% Technology US £57,828,095.93 156,865
    Amazon.com Inc 2.74523% Consumer Discretionary US £35,492,470.87 202,915
    Alphabet Inc 2.33878% Technology US £30,237,581.93 123,587
    Broadcom Inc 2.28287% Technology US £29,514,681.43 97,668
    Alphabet Inc 1.88052% Technology US £24,312,843.52 99,476
    Meta Platforms Inc 1.71828% Technology US £22,215,251.93 46,170
    Tesla Inc 1.48533% Consumer Discretionary US £19,203,514.23 59,497
    Eli Lilly & Co 1.08785% Health Care US £14,064,533.76 16,951

    Total allocation percentages shown in the holdings details or the spreadsheet may not equal 100%, due to rounding or omission of cash and/or futures contracts.

    The value of investments, and the income from them, may fall or rise and investors may get back less than they invested.

    Weighted equity exposures exclude any temporary cash investments and equity index derivatives.

    Prices and distribution

    Prices

    NAV Price (GBP)
    £354.51
    Change
    -£2.29-0.64%
    At closure 18 Dec 2025
    NAV 52-week high
    £364.86
    At closure 19 Dec 2025
    NAV 52-week low
    £265.48
    At closure 19 Dec 2025
    NAV 52-week difference
    £99.39
    Change
    +27.24%
    At closure 19 Dec 2025
    Historical Prices

    -

    Inception date

    07 Mar 2016

    Date NAV (GBP)
    18 Dec 2025 £354.5130
    17 Dec 2025 £356.8036
    16 Dec 2025 £354.5613
    15 Dec 2025 £358.9551
    12 Dec 2025 £360.4123
    11 Dec 2025 £357.9468
    10 Dec 2025 £358.2065
    09 Dec 2025 £358.3117
    08 Dec 2025 £359.9464
    05 Dec 2025 £358.8818

    Distribution history

    Distribution frequency

    —

    Historical performance 30 Nov 2025

    1.18%

    All dividends are reinvested for the "Accumulation" shares.

    The value of investments, and the income from them, may fall or rise and investors may get back less than they invested.

    Purchase information

    Currency

    Base currency: GBP

    Fund codes

    • Bloomberg: VANDXBG
    • Citi: ME2Y
    • ISIN: IE00BYMSV959
    • MEX ID: VIXXA
    • SEDOL: BYMSV95

    The value of investments, and the income from them, may fall or rise and investors may get back less than they invested.

    SEDOL and SEDOL Masterfile® are registered trademarks of the London Stock Exchange Group PLC. SEDOL data was extracted from the London Stock Exchange SEDOL Masterfile®.